Tenax Therapeutics (FRA:YBO0) ROE % Adjusted to Book Value: -21.96% (As of Mar. 2026)


FRA:YBO0 Tenax Therapeutics Inc FRA:YBO0
34 GF Score
Price €10.90
! 2 Warning Signs
View Full Analysis

What is Tenax Therapeutics ROE % Adjusted to Book Value?

Tenax Therapeutics FRA:YBO0 +14.74% 34 ROE % Adjusted to Book Value is -21.96% as of Mar. 2026. GuruFocus rates FRA:YBO0 with a GF Score™ of 34/100. The stock has 2 warning signs investors should review.

Tenax Therapeutics's ROE % for the quarter that ended in Mar. 2026 was -59.72%. Tenax Therapeutics's PB Ratio for the quarter that ended in Mar. 2026 was 2.72. Tenax Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was -21.96%.

Tenax Therapeutics ROE % Adjusted to Book Value Related Terms

Tenax Therapeutics ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Tenax Therapeutics's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tenax Therapeutics ROE % Adjusted to Book Value Chart

Tenax Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only -129.52 -118.06 -24.66 0.00 0.00

Tenax Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -21.96

FRA:YBO0 vs RZLT, PRLD, NAGE: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, Tenax Therapeutics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tenax Therapeutics ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tenax Therapeutics's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Tenax Therapeutics's ROE % Adjusted to Book Value falls into.


FRA:YBO0
34GF Score
Tenax Therapeutics Inc FRA:YBO0
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tenax Therapeutics ROE % Adjusted to Book Value Calculation

Tenax Therapeutics's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-52.61% / N/A
=N/A

Tenax Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-59.72% / 2.72
=-21.96%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -21.96% mean?
Tenax Therapeutics (FRA:YBO0) has a ROE % Adjusted to Book Value of -21.96% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Tenax Therapeutics and its competitors.
Is Tenax Therapeutics' ROE % Adjusted to Book Value too high?
Tenax Therapeutics' current ROE % Adjusted to Book Value is -21.96%. Overall, Tenax Therapeutics has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Tenax Therapeutics' ROE % Adjusted to Book Value compare to RZLT and PRLD?
Tenax Therapeutics' ROE % Adjusted to Book Value of -21.96% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Tenax Therapeutics and its competitors. Tenax Therapeutics's current ROE % Adjusted to Book Value is -21.96%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tenax Therapeutics stock overvalued right now?
Tenax Therapeutics (FRA:YBO0) has a current ROE % Adjusted to Book Value of -21.96%. The current ROE % Adjusted to Book Value is -21.96%. Tenax Therapeutics' overall GF Score™ is 34/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Tenax Therapeutics (FRA:YBO0), the current ROE % Adjusted to Book Value is -21.96% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Tenax Therapeutics Business Description

Other Exchanges TENX:USA
Address 101 Glen Lennox Drive, Suite 300, Chapel Hill, NC, USA, 27517
Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.
34GF Score

Get the complete analysis for FRA:YBO0

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€10.90
Price